Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
imatinib + nilotinib + dasatinib + radotinib
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This is a theoretical combination of four tyrosine kinase inhibitors (TKIs): imatinib, nilotinib, dasatinib, and radotinib. Each of these drugs individually targets the BCR-ABL tyrosine kinase, which is the product of the Philadelphia chromosome found in chronic myeloid leukemia (CML). While combinations of two TKIs (such as imatinib with dasatinib) have been studied clinically, there is no established clinical use or research on the simultaneous use of all four of these TKIs together.
02
Targets
ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)
Beyond the preview
Go deeper on imatinib + nilotinib + dasatinib + radotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on imatinib + nilotinib + dasatinib + radotinib.